CLYM116 Phase 1 data backs every-12-week dosing plan
Initial Phase 1 results for CLYM116 in healthy volunteers reported robust biomarker suppression, favorable safety, and a long half-life supporting every-12-week dosing; Phase 2 NAVIGATE-2 will confirm ahead of Phase 3.
Initial Phase 1 results for CLYM116 in healthy volunteers showed robust APRIL and immunoglobulin suppression, a favorable safety profile, and a long half-life supporting every-12-week dosing.
The ongoing Phase 2 NAVIGATE-2 study aims to confirm these findings and enable rapid advancement to Phase 3…